retatrutide phase 2 trial new england journal of medicine Efficacy and safety retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 New Phase 3 retatrutide data

G., Pekas, E

The assessment of TEAE severity was based on the Amgen standard grading scale as follows: mild (aware of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activity) and severe (incapacitating with inability to do work or do usual activity)

Yet, the quest for effective and safe weight loss solutions persists, and GLP-1 has continued to make waves since its FDA approval in 2021 as a highly effective weight loss treatment

CrossRef Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li npj Digital Medicine .2026;[Epub] CrossRef Morphological characterization of a novel model of steatohepatitis in the FAH -/- pig Silvana N

GLP-1 agonists can trigger acute kidney injury in dehydrated states and pose thyroid considerations